Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.5 USD | +2.72% | +13.64% | +225.97% |
Financials (USD)
Sales 2024 * | 14.77M | Sales 2025 * | 12.14M | Capitalization | 2.82B |
---|---|---|---|---|---|
Net income 2024 * | -292M | Net income 2025 * | -326M | EV / Sales 2024 * | 191 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 232 x |
P/E ratio 2024 * |
-9.18
x | P/E ratio 2025 * |
-8.67
x | Employees | 253 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.29% |
Latest transcript on Avidity Biosciences, Inc.
1 day | +2.72% | ||
1 week | +13.64% | ||
Current month | +22.25% | ||
1 month | +28.04% | ||
3 months | +108.04% | ||
6 months | +363.11% | ||
Current year | +225.97% |
Managers | Title | Age | Since |
---|---|---|---|
Troy Wilson
FOU | Founder | 55 | 12-11-12 |
Sarah Boyce
CEO | Chief Executive Officer | 52 | 19-09-30 |
Michael MacLean
DFI | Director of Finance/CFO | 58 | 20-05-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arthur Levin
BRD | Director/Board Member | 70 | 13-09-30 |
Carsten Boess
BRD | Director/Board Member | 57 | 20-04-12 |
Edward Kaye
BRD | Director/Board Member | 75 | 19-08-21 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.11% | 0 M€ | 0.00% | - | |
0.08% | 0 M€ | 0.00% | - | |
0.08% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 29.5 | +2.72% | 895,645 |
24-05-16 | 28.72 | -2.68% | 1,074,988 |
24-05-15 | 29.51 | +2.08% | 1,680,704 |
24-05-14 | 28.91 | +11.11% | 1,798,074 |
24-05-13 | 26.02 | +0.23% | 783,775 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+225.97% | 2.82B | |
-2.32% | 90.45B | |
+3.68% | 41.45B | |
-10.90% | 33.57B | |
+58.05% | 25.73B | |
-19.56% | 14.73B | |
-9.06% | 12.82B | |
-11.34% | 11.7B | |
-43.53% | 11.44B | |
+3.75% | 8.79B |
- Stock Market
- Equities
- RNA Stock